Levels of absolute survival benefit for systemic therapies of advanced cancer: a call for standards
- 30 June 2003
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (9) , 1194-1198
- https://doi.org/10.1016/s0959-8049(03)00119-9
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Meta-analyses of randomised clinical trials in oncologyThe Lancet Oncology, 2001
- Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patientsBritish Journal of Haematology, 2001
- Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trialThe Lancet, 2001
- Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysisBMJ, 2000
- Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta‐analysis of three randomized trialsBritish Journal of Haematology, 2000
- Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized TrialsJNCI Journal of the National Cancer Institute, 1999
- A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemiaBritish Journal of Haematology, 1998
- Uncontrolled Pearls, Controlled Evidence, Meta-Analysis and the Individual Patient☆Journal of Clinical Epidemiology, 1998
- Reappraisal of Hepatic Arterial Infusion in the Treatment of Nonresectable Liver Metastases From Colorectal CancerJNCI Journal of the National Cancer Institute, 1996
- The Role of Maintenance Therapy in Disseminated Testicular CancerNew England Journal of Medicine, 1981